ArticleEuropean journal of nuclear medicine and molecular imaging2026
A phase I study to evaluate the dosimetry and safety of [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05974579 (A Single Center, Open Label Study to Evaluate Biodistribution, Pharmacokinetics and Safety of [89Zr]Zr-DFO-AP-101 PET), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single Center, Open Label Study to Evaluate Biodistribution, Pharmacokinetics and Safety of [89Zr]Zr-DFO-AP-101 PET (Positron Emission Tomography) in Healthy Volunteers and Amyotrophic Lateral Sclerosis (ALS) Patients
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
purposeMisfolded superoxide dismutase-1 (mSOD1) is an abnormal protein observed in amyotrophic lateral sclerosis (ALS) and constitutes a therapeutic target. The present study evaluated the biodistribution, dosimetry, and safety of a new antibody-based radiopharmaceutical, [89Zr]Zr-DFO-AP-101, targeting mSOD1.
methodsSeven control participants and one patient with ALS received 41 ± 3 MBq of [89Zr]Zr-DFO-AP-101. They were followed up with five whole-body positron emission tomography (PET) scans over 10 days. Semi-automatic segmentation was performed on the images to derive time-activity curves, radiotracer effective half-life and dose exposure.
resultsTotal elimination of the radiotracer (urinary and hepatobiliary) was 25–30% after three days and reached a plateau after a week. At 2 h post-injection, ~ 60% of the radiopharmaceutical remained in the blood pool, with a biological half-life of 53 h. The liver was the dose-limiting organ with 0.84 mSv/MBq in males, 1.07 mSv/MBq in females, and 1.23 mSv/MBq in the female ALS patient. The spleen, adrenal glands, kidney, and heart wall were the other most irradiated organs. Average effective doses were 0.21 mSv/MBq for males, 0.28 mSv/MBq for females, and 0.31 mSv/MBq for the female ALS patient. Tracer uptake in the spinal cord and vertebrae of the ALS patient, on Days 7 and 10, was more than one standard deviation higher than for the control female participants. No serious adverse event was observed.
conclusionsThe single dose of [89Zr]Zr-DFO-AP-101 was safe for all participants. It provided good image quality for the biodistribution and dosimetry analysis over 10 days. Further studies are needed to demonstrate the efficacy of ALS diagnosis through PET imaging. https://www.clinicaltrials.gov/study/NCT05974579.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.